- Home
- CIFR vs PRCT Comparison
CIFR vs PRCT Comparison
Compare CIFR & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- PRCT
- Stock Information
- Founded
- CIFR 2021
- PRCT 2009
- Country
- CIFR United States
- PRCT United States
- Employees
- CIFR N/A
- PRCT N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- PRCT Medical Specialities
- Sector
- CIFR Finance
- PRCT Health Care
- Exchange
- CIFR Nasdaq
- PRCT Nasdaq
- Market Cap
- CIFR 2.1B
- PRCT 2.2B
- IPO Year
- CIFR N/A
- PRCT 2021
- Fundamental
- Price
- CIFR $5.14
- PRCT $39.66
- Analyst Decision
- CIFR Strong Buy
- PRCT Buy
- Analyst Count
- CIFR 11
- PRCT 8
- Target Price
- CIFR $7.67
- PRCT $75.57
- AVG Volume (30 Days)
- CIFR 24.6M
- PRCT 1.6M
- Earning Date
- CIFR 08-07-2025
- PRCT 08-06-2025
- Dividend Yield
- CIFR N/A
- PRCT N/A
- EPS Growth
- CIFR N/A
- PRCT N/A
- EPS
- CIFR N/A
- PRCT N/A
- Revenue
- CIFR $158,849,000.00
- PRCT $274,950,000.00
- Revenue This Year
- CIFR $88.30
- PRCT $47.51
- Revenue Next Year
- CIFR $63.63
- PRCT $31.69
- P/E Ratio
- CIFR N/A
- PRCT N/A
- Revenue Growth
- CIFR 0.11
- PRCT 55.71
- 52 Week Low
- CIFR $1.86
- PRCT $37.12
- 52 Week High
- CIFR $7.77
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- CIFR 47.21
- PRCT 25.81
- Support Level
- CIFR $4.67
- PRCT $37.32
- Resistance Level
- CIFR $5.10
- PRCT $40.86
- Average True Range (ATR)
- CIFR 0.36
- PRCT 2.63
- MACD
- CIFR -0.12
- PRCT -1.06
- Stochastic Oscillator
- CIFR 27.35
- PRCT 12.18
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.